PET3D – PET Imaging in Drug Design and Development – H2020
What and where is the disease?
Is the disease accurately targeted by the therapy?
However, there is a world shortage of scientists with the necessary expertise to become research leaders in this area and answer these questions. All the major pharmaceutical companies use PET to support the development of drugs but the shortage means it is very difficult for companies and universities to recruit.
The PET3D consortium is addressing this shortage and will provide top-quality training to the next generation of translational PET imaging scientists. The 15 cutting-edge research projects will span all of the main therapeutic areas in which PET imaging plays a key role, namely oncology, cardiovascular and neuroscience, and will make use of the whole portfolio of molecular formats available in modern PET imaging, such as small molecules, peptides, nanoparticles and antibody formats using different PET radioisotopes.
Keywords: ANTIBODY FORMATS; CARDIOVASCULAR; DRUG DESIGN; DRUG DEVELOPMENT; ESR; ETN; EUROPEAN COMMISSION; ITN; MARIE SKLODOWSKA CURIE; NANOPARTICLES; NEUROSCIENCE; ONCOLOGY; PEPTIDES; PET; PET IMAGING; PET3D; POSITRON EMISSION TOMOGRAPHY; SMALL MOLECULES; TRAINING NETWORK
Document Type: Research Article
Publication date: October 1, 2017
Impact is a series of high-quality, open access and free to access science reports designed to enable the dissemination of research impact to key stakeholders. Communicating the impact and relevance of research projects across a large number of subjects in a content format that is easily accessible by an academic and stakeholder audience. The publication features content from the world's leading research councils, policy groups, universities and research projects. Impact is published under a CC-BY Creative Commons licence.
- Subscribe to this Title
- Terms & Conditions
- Disseminating research in Impact
- Information about Impact
- Ingenta Connect is not responsible for the content or availability of external websites